
Yunkang Group Limited
2325.HKHKSEHealthcareMedical - Diagnostics & Research
最新数据
HK$0.625
−HK$0.01 · -1.65%
2325.HK公司概览
盘中时间采用HKT。市场数据可能有所延迟。
公司概况
公司网站Yunkang Group Limited, established in 2008 and headquartered in Guangzhou, People's Republic of China, operates as a comprehensive provider of medical operational services. The company offers a wide range of diagnostic testing solutions to medical institution alliances, which encompass assisting with the setup and enhancement of diagnostic centers, developing standard operating procedures for testing, delivering expert diagnostic consultations and staff training, sourcing necessary equipment, implementing smart Internet of Things technology, and providing logistics support. For diagnostic outsourcing, Yunkang Group conducts diverse tests, including pathology examinations; infectious disease diagnostics for conditions such as hepatitis B, tuberculosis, human papillomavirus, Epstein-Barr virus, rabies, and respiratory pathogens (via nucleic acid testing); genetic and reproductive health screenings; and routine diagnostic assessments for chronic ailments like kidney, blood, autoimmune, and endocrine metabolic diseases. Furthermore, the company caters to financial institutions and insurance firms by offering personalized diagnostic testing, medical report interpretation, and hospital referral services. Yunkang Group's capabilities also extend to information technology, medical logistics, procurement of medical equipment, healthcare technology development, and various project investments. These services are delivered through its network of independent clinical laboratories and integrated on-site diagnostic facilities.
- 行业
- Medical - Diagnostics & Research
- 部门
- Healthcare
- 总部
- CN
- 首席执行官
- Yong Zhang
- 上市以来
- 2022年5月18日
- 雇员
- 1,064
市场位置
- 成交量
- 1.5万
- 0.11× 平均值
- 平均成交量
- 14.08万
- 日均成交量
- 市值
- 3.48亿 HKD
- 贝塔
- -0.8
- 市场参考 1
财务数据
财务快照
最近十二个月估值与收益率
- 企业价值
- -3.74亿 CNY
- 市盈率(TTM)
- 102.05×
- 市净率(TTM)
- 0.27×
- 市销率(TTM)
- 0.5×
- EV/EBITDA
- -3.05×
- 盈利收益率
- 0.56%
- 自由现金流收益率
- 47.30%
- 股息率
- 0.00%
盈利能力和效率
- 毛利率
- 30.40%
- 营业利润率
- 5.48%
- 净利润率
- 0.49%
- 净资产收益率
- 0.25%
- 资产收益率
- 0.11%
- 投入资本回报率
- 0.99%
财务健康
- 负债权益比
- 0.6×
- 流动比率
- 1.59×
财务报表
利润率趋势
盈利能力占已公布营收的百分比。
损益趋势
营收
营业利润
净利润
| 项目(CNY) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6.01亿 CNY | 7.12亿 CNY | 8.92亿 CNY | 37.56亿 CNY | 16.97亿 CNY |
| 销货成本 | 4.19亿 CNY | 5.01亿 CNY | 5.66亿 CNY | 29.01亿 CNY | 9.78亿 CNY |
| 毛利 | 1.83亿 CNY | 2.11亿 CNY | 3.26亿 CNY | 14.67亿 CNY | 10.66亿 CNY |
| 研究与开发 | 5187.8万 CNY | 5741.51万 CNY | 6111.85万 CNY | 9473.2万 CNY | 4394.3万 CNY |
| 销售、一般及管理费用 | 3.05亿 CNY | 4.45亿 CNY | 3.42亿 CNY | 6.99亿 CNY | 4.25亿 CNY |
| 营业费用 | 1.5亿 CNY | 9.63亿 CNY | 3.78亿 CNY | 8.49亿 CNY | 4.41亿 CNY |
| 利息收入 | 890.3万 CNY | 1015.9万 CNY | 932.5万 CNY | 518万 CNY | 1075.1万 CNY |
| 利息支出 | 3487.6万 CNY | 4928.2万 CNY | 4356万 CNY | 1985.1万 CNY | 1722.5万 CNY |
| 折旧和摊销 | 3252.9万 CNY | 7339.1万 CNY | 6832万 CNY | 1.29亿 CNY | 3941.9万 CNY |
| 营业利润 | 3294.8万 CNY | −7.52亿 CNY | −5257.6万 CNY | 4.59亿 CNY | 4.58亿 CNY |
| 净利润 | 292万 CNY | −7.92亿 CNY | −1.02亿 CNY | 3.77亿 CNY | 3.81亿 CNY |
公司数据更新于 2026年8月24日。
继续GoAI的研究
在 GoAI 中研究2325.HKresearch.disclaimer